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ABSTRACT 
Carrier Detection and phenotypic expression in a family with 
hereditary coproporphyria 
Introduction: Hereditary coproporphyria (HCP) is an autosomal dominant disorder that 
results from defects in the enzyme coproporphyrinogen oxidase (CPOX). A major 
clinical feature is neurologic damage that leads to peripheral and autonornic 
neuropathies and psychiatric manifestations, accompanied occasionally by cutaneous 
skin lesions. Hep symptoms are usually triggered by environmental factors such as 
dnlgs and hormones. However, the penetrance is low meaning that m.ost patients remain 
asymptomatic most of their lives. This makes it more difficult to diagnose 
asymptomatic HCP patients by solely relying on biochemical methods. The aim of this 
study was to genetically screen carriers in a family with Hep and design a questionnaire 
to identify subtle porphyria syrnptorlls. 
Methods: Mutation screening was calTied out in a family of thirty nlembers, two of 
whom were symptonlatic for Hep. The entire CPOX gene of the proband was screened 
for mutations. A questionnaire \vas designed and completed by 26 participants to review 
the clinical picture and life style of patients and was cornpared with the genetic data. 
Result,,: A novel mutation was identified in exon 5 at c.l 064A>C causing a substitution 
in atnino acid 355 from glutamine to proline (p.Q355P). Sequencing results revealed 
that sixteen out of thirty members of this family were carriers of the mutation. Porphyria 
related symptorns were noted to be as common in males as in females with the 
mutation. 
Conclusions: Patients with the Q355P mutation reported more symptoms than those 
without the mutation. Females reportedly are more likely to exhibit acute porphyria 
symptoms due to hormonal factors. However, it was noted that the number of synlptoms 
reported by males with the mutation was more than that reported by fernales with the 
mutation. In this small sample cohort, these results suggest that environmental factors 
rather than endocrine factors playa role in the phenotypic expression of this mutation. 
Carriers are at risk of acute attacks; identifying thenl is beneficial because they can be 
given prior advice of preventative measures. 
Xl 
